DGAP-Adhoc

4SC AG announces subscription price for new shares from current capital increase

4SC AG / Key word(s): Capital Increase/Financing

02.07.2015 22:14

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc release pursuant to Section 15 of the German Securities Trading Act
(Wertpapierhandelsgesetz, WpHG)

NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN THE UNITED STATES,
AUSTRALIA, CANADA OR JAPAN.

4SC AG announces subscription price for new shares from current capital
increase

- Subscription price set at EUR 4.00 per new share

- Subscription period scheduled to end on 6 July 2015 at 24:00 hrs.
midnight (CEST)

Planegg-Martinsried, Germany, 2 July 2015 - The Management Board of 4SC AG
(Frankfurt, Prime Standard: ISIN DE000A14KL72, VSC) today resolved, with
the approval of the Supervisory Board, the subscription price for the
ongoing cash capital increase at EUR 4.00 per new share. As announced in
the Company's ad hoc release on 22 June 2015, the subscription price was
determined taking into account the volume-weighted average price (VWAP) of
4SC AG in the XETRA electronic trading system on the Frankfurt Stock
Exchange from the beginning of the subscription period on 23 June 2015
until close of trading on 2 July 2015, less a discount. The VWAP of the 4SC
share in the relevant period was EUR 4.53, hence the granted discount
amounts to 11.7%. The ongoing subscription period for the new shares is
scheduled to end at 24:00 hrs. midnight (CEST) on 6 July 2015. Any new
shares not subscribed for will be offered to selected institutional
investors as private placements.

4SC AG intends to issue up to approximately 8.2 million new shares by cash
contributions for the further development of its existing research and
development programmes, in particular for the financing of a planned
clinical Phase II trial with its lead anti-cancer agent resminostat in the
tumour indication of cutaneous T-cell lymphoma (CTCL).

In addition, the Company plans to issue up to approximately 2.0 million new
shares (Consideration Shares) for the same issue price of EUR 4.00 as part
of a capital increase against contributions in kind in order to swap a
substantial portion of an existing loan from major shareholder Santo
Holding (Deutschland) GmbH into equity. Overall, through both capital